Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Last trade$10.83
Day change+$0.80 (+7.98%)
Day range$10.02 – $11.22
Volume243,137
Market cap$197M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$196.83M
Price / earnings
—
Price / book
0.71×
Price / sales
4.83×
EV / sales
-1.54×
EV / EBITDA
0.87×
Profitability
Earnings per share
-$3.15
Return on assets
-20.08%
Return on equity
-22.12%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
18.14×
Quick ratio
18.14×
Cash ratio
16.36×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$48.27M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for KROS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$40.01M
$0
$367K
$385K
$14.26M
$18.17M
$211.25M
$3.04M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$40.01M
$0
$367K
$385K
$14.26M
$18.17M
$211.25M
$3.04M
Selling, general and administrative
$6.7M
$8.61M
$10.15M
$11.74M
$10.13M
$14.48M
$10.5M
$10.67M
Research and development
$20.49M
$22.33M
$16.1M
$17.91M
$19.52M
$43.5M
$48.71M
$45.63M
Total operating expenses
$27.19M
$30.94M
$26.24M
$29.66M
$29.65M
$57.99M
$59.21M
$56.3M
Operating income
$12.82M
-$30.94M
-$25.88M
-$29.27M
-$15.38M
-$39.82M
$152.04M
-$53.25M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$14.93M
-$28.71M
-$23.71M
-$24.98M
-$8.7M
-$32.92M
$158.49M
-$45.73M
Income taxes
$772K
$0
$0
-$1.51M
-$1.42M
-$2.22M
$10.04M
$300K
Net income
$14.15M
-$28.71M
-$23.71M
-$23.46M
-$7.28M
-$30.7M
$148.45M
-$46.03M
Net income attributable to common shareholders
$14.15M
-$28.71M
-$23.71M
-$23.46M
-$7.28M
-$30.7M
$148.45M
-$46.03M
EBITDA
$13.2M
-$30.54M
-$25.47M
-$28.87M
-$14.99M
-$39.45M
$152.38M
-$52.92M
Basic earnings per share
$0.71
-$1.45
-$1.21
-$0.87
-$0.18
-$0.76
$3.66
-$1.14
Diluted earnings per share
$0.70
-$1.45
-$1.21
-$0.80
-$0.18
-$0.76
$3.62
-$1.14
Recent news
Company coverage with links to the original publishers.
Keros Therapeutics reported Q3 2026 earnings of $0.7 per share, beating consensus estimates of a $0.96 loss, with a 172.92% earnings surprise. Revenues reached $40.01 million, surpassing estimates by 197.47% compared to $14.26 million year-ago. However, the stock has underperformed the market, down 46.8% year-to-date versus the S&P 500's 12.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Bristol Myers is relying on its growth portfolio including Reblozyl, Opdivo, and other key drugs to drive top-line growth as legacy drug sales decline. Reblozyl sales reached nearly $1.3 billion in H1 2026, up 23% year-over-year, with potential for further growth from new indications. However, the company faces increasing competition from Geron's Rytelo and Keros Therapeutics' elritercept in the MDS and myelofibrosis treatment space.
Keros Therapeutics announced the first patient dosing in its phase II study evaluating rinvatercept for Duchenne muscular dystrophy (DMD). The study will assess safety, tolerability, and functional improvements, with initial data expected in H1 2027. The company is also advancing rinvatercept development for ALS treatment and has a licensing agreement with Takeda Pharmaceutical for its second candidate, elritercept, with potential milestone payments exceeding $1.1 billion.
Keros Therapeutics reported a Q2 2026 loss of $1.45 per share, missing consensus estimates, with revenues falling to zero from $18.2 million year-over-year. The company has no marketed products and is focusing on pipeline development. With $257.6 million in cash, the company expects runway into H1 2028. The stock received a Zacks Rank #3 (Hold) rating with an F VGM Score.
DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.